Alchemab is proud to be part of the Oxford BioEscalator cohort working on therapeutics against #COVID19 bioescalator.ox.ac.uk/news/agile-sta…

Jane Osbourn OBE, our CSO, will be speaking as the next guest on Rock Stars of R&D! See details below if you’d like to join to listen this Friday, August 14, 2020 at 7pm BST: lnkd.in/dt7b94w

Alchemab is delighted to be nominated as a finalist in the ‘Best Start-Up Biotech’ category for this year’s OBN Awards which recognises outstanding achievement in life sciences. Huge congratulations to our super team for their hard work and dedication over the last few months!

We are delighted to announce a partnership between Alchemab and the Alberta Machine Intelligence Institute (Amii), a global leader in machine intelligence . amii.ca/latest-from-am…

Today we announce that the UK BIA #AntibodyTaskforce has identified antibodies with great potential to treat and protect against #COVID19, differentiated antibody combinations will be taken forward for further development as an antibody cocktail.👇 bia.me/37Ojv9b

The UK BIA #AntibodyTaskforce is a world-leading consortium of biotech companies, charities and academia based across the UK who share a joint commitment to help fight the #COVID19 pandemic. #COVID19Antibodies Find out more👇 biacovid19.org/antibodies.html

Very proud to feature two of Alchemab's team in this year’s Movers and Shakers in BioBusiness report, Jane Osbourn OBE and Olivia Cavlan. Congratulations to Miranda Weston-Smith and the BioBeat team for compiling such a super report! lnkd.in/dmdGUKC

Delighted to have been added to the list of most disruptive companies in Cambridge - bit.ly/2K3056R Business Weekly - thank you for the recognition!

We’re excited to announce our partnership with EPAD! Together we will uncover new science and further the discovery of innovative treatments for Alzheimer’s Disease

#WomenInScience #InternationalWomensDay

Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease with Innovate UK grant Exciting scientific and advanced analytic/bioinformatic opportunities to join the team – see lnkd.in/d99PXQ6 lnkd.in/dgahkxH

We are thrilled to announce that we’ve raised £60m ($82m) in Series A funding led by RA Capital Management, with Lightstone Ventures and DHVC, joined by existing investors DCVC Bio, Dementia Discovery Fund and SV Health Investors who led the Seed round. lnkd.in/dX7YgnD

Alchemab partnering with AstraZeneca to advance prostate cancer therapies #antibodies #drugdiscovery #prostatecancer #biotech lnkd.in/ddBWh-H

We are THRILLED to have been awarded ‘best biotech start-up’ as part of the OBN (UK) Ltd Awards! The award is really a reflection of our fantastic, dedicated and diverse team - all of whom have contributed to making this possible. #biotech #OBNAwards #startups